ÂÜÀòÂÒÂ×

Sandy Harm is the current Chief Operating Officer at ENB Therapeutics. Prior to this, Sandy was a Biotechnolgy Consultant from January 2015 to December 2016, providing input on basic research (in vivo), early clinical research and market-potential for drug development of potential licensee candidates. Sandy has also worked as the Director, Strategy & Operations, Medical Affairs for Merck from August 2006 to December 2014 where they were responsible for Medical Affairs field strategy, operations and integration for all therapeutic areas within the U.S. Medical Affairs organization. Sandy has a wealth of experience in restructuring medical staff, designing and developing scientific leader market analysis, and sizing and mapping positions. Sandy has also provided oversight to multiple cross-functional implementation teams including: training, customer relationship management (CRM) database customization, resource development, medical services, research and investigator initiated studies, HR, finance, business practices & compliance, and others.

Sandy Harm has a Master of Business Administration (MBA) from Saint Joseph's University and a Master of Science (MS) in Biology from Villanova University. Sandy is also certified to teach Biology in Pennsylvania secondary schools.

Sandy Harm reports to Sumayah Jamal, President, Co-founder, Chief Scientific Officer.